London
11 °C
Manchester
Glasgow
10 °C
Dublin
11 °C
Belfast
Washington
Denver
2 °C
Atlanta
Dallas
Houston Texas
18 °C
New Orleans
El Paso
Phoenix
Los Angeles
7 °C
24 °C
19 °C
-24 °C
-29 °C
8 °C
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
NYSE - LSE
| RIO | 1.55% | 77.19 | $ | |
| BTI | -0.21% | 57.17 | $ | |
| CMSC | -0.34% | 23.26 | $ | |
| RBGPF | -2.23% | 80.22 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| NGG | 1.8% | 77.16 | $ | |
| RYCEF | 1.48% | 14.86 | $ | |
| RELX | -0.64% | 40.56 | $ | |
| BP | 2.06% | 34.47 | $ | |
| VOD | 0.86% | 12.81 | $ | |
| BCC | 0.59% | 76.29 | $ | |
| AZN | -1.66% | 89.86 | $ | |
| GSK | -0.14% | 48.71 | $ | |
| BCE | -0.78% | 23.15 | $ | |
| CMSD | -0.43% | 23.28 | $ | |
| JRI | -0.6% | 13.43 | $ |
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
(P.Davis--TAG)
